Medicina
Departamento
Carl von Ossietzky University of Oldenburg
Oldenburg, AlemaniaPublicaciones en colaboración con investigadores/as de Carl von Ossietzky University of Oldenburg (10)
2024
-
Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study
Future oncology (London, England), Vol. 20, Núm. 6, pp. 297-306
2022
-
Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Annals of Oncology, Vol. 33, Núm. 11, pp. 1168-1178
2019
-
Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment
Journal of the American College of Cardiology, Vol. 73, Núm. 4, pp. 444-453
-
Comparison of Major Adverse Cardiac Events between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients with or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial
JAMA Cardiology, Vol. 4, Núm. 9, pp. 857-864
-
Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserve–Guided Revascularization Strategy
JACC: Cardiovascular Interventions, Vol. 12, Núm. 20, pp. 2035-2046
2018
-
Influence of hydrostatic pressure on intracoronary indices of stenosis severity in vivo
Clinical Research in Cardiology, Vol. 107, Núm. 3, pp. 222-232
-
Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes
JACC: Cardiovascular Interventions, Vol. 11, Núm. 15, pp. 1437-1449
2017
-
Effect of Coronary Anatomy and Hydrostatic Pressure on Intracoronary Indices of Stenosis Severity
JACC: Cardiovascular Interventions, Vol. 10, Núm. 8, pp. 764-773
-
Use of the instantaneous wave-free ratio or fractional flow reserve in PCI
New England Journal of Medicine, Vol. 376, Núm. 19, pp. 1824-1834
2013
-
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: The RESPECT trial
Clinical Cancer Research, Vol. 19, Núm. 9, pp. 2541-2550